Skip to main content
SpringerLink
Log in

Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis

  • Chapter
Clinical Trials in Rheumatoid Arthritis and Osteoarthritis

Part of the book series: Clinical Trials ((CLINICAL))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003;79:377–383.

    Article  PubMed  CAS  Google Scholar 

  2. National Center for Health Statistics. Prevalence of osteoarthrits in adults by age, sex, race and geographic area: United States 1960–62. Vital Health Stat 11(15).

    Google Scholar 

  3. Murray CJL, Lopez Ad, eds. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organisation and the World Bank; 1996.

    Google Scholar 

  4. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. Oxford: Oxford {University} Press; 1993.

    Google Scholar 

  5. Heberden W. Commentaries on the history and causes of disease. London: Payne; 1802.

    Google Scholar 

  6. Haygarth J. A clinical history of diseases. II. Nodosity of the joints. London: Gadell and Davies; 1805.

    Google Scholar 

  7. Stecher RM. Heberden’s nodes: heredity in hypertrophic arthritis of the finger joints. Am J Med Sci 1941:201;801–809.

    Article  Google Scholar 

  8. Kellgren JH, Moore R. Generalised osteoarthritis and Heberden’s nodes. Br Med J 1952;1:181–187.

    PubMed  CAS  Google Scholar 

  9. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16(4):494–502.

    PubMed  CAS  Google Scholar 

  10. Lawrence JS, Bremmer JM, Bier F. Osteoarthrosis: prevalence in the population and {relationships} between symptoms and X-ray changes. Ann Rheum Dis 1966;25:1–24.

    PubMed  CAS  Google Scholar 

  11. Charnley J. Arthroplasty of the hip: a new operation. Lancet 1961;1:1129–1132.

    Article  PubMed  CAS  Google Scholar 

  12. McKee GK, Watson-Farrar J. Replacement of arthritic hips by the McKee-Farrar prosthesis. J Bone Joint Surg Br 1966;48(2):245–259.

    PubMed  CAS  Google Scholar 

  13. Mankin H. The reaction of articular cartilage to injury and osteoarthritis. N Engl J Med 1990;291:1285.

    Article  Google Scholar 

  14. Dean D. Proteinase-mediated cartilage damage in osteoarthritis. Semin Arthritis Rheum 1991;20(Suppl):2.

    Article  PubMed  CAS  Google Scholar 

  15. Pelletier J, Roughley P, Dibattista JA, et al. Are cytokines involved in osteoarthritic patho- logy? Semin Arthritis Rheum 1991;20(Suppl):63.

    Article  Google Scholar 

  16. Martel-Pelletier J, Pelletier JP, Cloutier JM, et al. Neutral protease capable of proteoglycan digesting activity in osteoarthritic and normal human cartilage. Arthritis Rheum 1984;27:305.

    Article  PubMed  CAS  Google Scholar 

  17. Pelletier JP, Martel-Pelletier J, Cloutier JM, et al. Proteoglycan-degrading acid metalloproteinase activity in human osteoarthritic cartilage, and the effect of intraarticular steroid injections. Arthritis Rheum 1987;19:541.

    Article  Google Scholar 

  18. Dean D, Woessner J Jr. Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J 1984;218:277.

    PubMed  CAS  Google Scholar 

  19. Dean D, Martel-Pelletier J, Pelletier JP, et al. Evidence of metalloproteinase and metalloproteinase inhibitor (TIMP) imbalance in human osteoarthritic cartilage. J Clin Inv 1989;84:678.

    Article  CAS  Google Scholar 

  20. Wolff J. The law of bone remodelling. New York: Springer-Verlag; 1986.

    Google Scholar 

  21. American College of Rheumatology Subcomitteee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthrits Rheum 2000;43(9):1905–1915.

    Google Scholar 

  22. Ettinger WH Jr, Bums R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis: the Fitness Arthritis and Seniors Trial (FAST). JAMA 1997;277:25–31.

    Article  PubMed  Google Scholar 

  23. Van Baar ME, Dekker J, Oostendorp RAB, et al. The effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized clinical trial. J Rheumatol 1998;25:2432–2439.

    PubMed  Google Scholar 

  24. Hurley MV, Scott DL, Rees J, et al. Sensorimotor changes and functional performance in patients with knee osteoarthritis. Ann Rheum Dis 1997;56:641–648.

    PubMed  CAS  Google Scholar 

  25. American Geriatrics Society Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons. J Am Geriatric Soc 1998;46:635–651.

    Google Scholar 

  26. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87–91.

    Article  PubMed  CAS  Google Scholar 

  27. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36: 1196–206.

    Article  PubMed  CAS  Google Scholar 

  28. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in patients with osteoarthritis of the knee. Semin Arthritis Rheum 1997;27:755–770.

    Article  Google Scholar 

  29. Eccles M, Freemantle N, Mason J, for the North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England Evidence Based Guideline Development Project: summary guideline for non-steroidal antiinflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998;317:526–30.

    PubMed  CAS  Google Scholar 

  30. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Available at http://www.nice.org.uk/pdf/coxiifullguidance.pdf. Accessed 14 April 2005.

    Google Scholar 

  31. Griessinger N, Sittl R, Likar R. Transdermal buprenorphime in clinical practice – a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21(8): 1147–1156.

    Article  PubMed  CAS  Google Scholar 

  32. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lignocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(suppl2):S13–S19.

    Article  PubMed  CAS  Google Scholar 

  33. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307–314.

    Article  PubMed  CAS  Google Scholar 

  34. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4–13.

    Article  PubMed  CAS  Google Scholar 

  35. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58365, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591–1602.

    Article  PubMed  CAS  Google Scholar 

  36. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921–1928.

    Article  PubMed  CAS  Google Scholar 

  37. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776–783.

    Article  PubMed  CAS  Google Scholar 

  38. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370–377.

    Article  PubMed  CAS  Google Scholar 

  39. Karim A, Tolbert D, Piergies A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. Arthritis Rheum 1998;41,9(Suppl):S315.

    Google Scholar 

  40. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332: 1302–1308.

    Article  PubMed  CAS  Google Scholar 

  41. Medicines and Healthcare Products Regulatory Agency. Cardiovascular safety of COX-2 inhibitors and non-selective NSAIDs. Available at {http://www.mhra.gov.uk/home/ideplg?ldcService=SS_GET_PAGE&nodeld=227}. Last accessed 1st January 2008.

    Google Scholar 

  42. Dalgin P, and the TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [abstract]. Arthritis Rheum 1997;40(Suppl 9):S86.

    Google Scholar 

  43. Roth SH. Efficacy and safety of tramadol HCI in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358–1363.

    PubMed  CAS  Google Scholar 

  44. Altman RD, Moskowitz RW, and the Hyalgan Study Group. Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998;25:2203–2212.

    Google Scholar 

  45. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213–225.

    Article  PubMed  CAS  Google Scholar 

  46. Kirwan JR, Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol 1997;11:769–794.

    Article  PubMed  CAS  Google Scholar 

  47. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:609–626.

    Article  PubMed  CAS  Google Scholar 

  48. Williams JM, Brandt KD. Triamcinolone hexacetonite protects against fibrillation and osteophyte formation following chemically induced cartilage damage. Arthritis Rheum 1985;28(11):1267–1274.

    Article  PubMed  CAS  Google Scholar 

  49. Pelletier JP, Martel-Pelletier J. Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1989;32(2):181–193.

    Article  PubMed  CAS  Google Scholar 

  50. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283(11):1469–1475.

    Article  PubMed  CAS  Google Scholar 

  51. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256.

    Article  PubMed  CAS  Google Scholar 

  52. Jordan KM, Arden NK, Docherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–1155.

    Article  PubMed  CAS  Google Scholar 

  53. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;(1):CD002946.

    Google Scholar 

  54. Fernandes JC, Martel-Pelletier J, Pelletier J-P. Gene therapy for osteoarthritis. Clin Orthop 2000;379(Suppl):S262–272.

    PubMed  Google Scholar 

  55. McMinn D, Treacy R, Lin K, Pynsent P. Metal on metal surface replacement of the hip: experience of the McMinn prosthesis. Clin Orthop 1996;329(Suppl):89–98.

    Google Scholar 

  56. Iorio R, Healy WL. Unicompartmental arthritis of the knee. J Bone Joint Surg Am 2003;85(7):1351–1364.

    PubMed  Google Scholar 

  57. McKeever DC. Tibial plateau prosthesis. Clin Orthop 1960;18:86–95.

    Google Scholar 

  58. Murray DW, Goodfellow JW, O’Connor JJ. The Oxford medial unicompartmental arthroplasty: a ten-year survival study. J Bone Joint Surg Br 1998;80(6):983–991.

    Article  PubMed  CAS  Google Scholar 

  59. Charnley J. The long-term results of low-friction arthroplasty of the hip performed as a primary intervention. J Bone Joint Surg Br 1972;54(1):61–76.

    PubMed  CAS  Google Scholar 

  60. Wroblewski BM. 15-21-year results of the Charnley low-friction arthroplasty. Clin Orthop 1986;211:30–35.

    PubMed  Google Scholar 

  61. Callaghan JJ, Forest EE, Olejniczak JP, et al. Charnley total hip arthroplasty in patients less than fifty years old: a twenty to twenty-five-year follow-up note. J Bone Joint Surg Am 1998;80(5):704–714.

    PubMed  CAS  Google Scholar 

  62. Charnley J, Cupic Z. The nine and ten year results of the low-friction arthroplasty of the hip. Clin Orthop Relat Res 1973;95:9–25.

    PubMed  Google Scholar 

  63. Charnley J, Halley DK. Rate of wear in total hip replacement. Clin Orthop 1955;Oct 170–179.

    Google Scholar 

  64. Harris WH, Schiller AL, Scholler JM, et al. Extensive localized bone resorption in the femur following total hip replacement. J Bone Joint Surg Am 1976;58(5):612–618.

    PubMed  CAS  Google Scholar 

  65. Charnley J, Follacci FM, Hammond BT. The long-term reaction of bone to self-curing acrylic cement. J Bone Joint Surg Br 1968;50(4):822–929.

    PubMed  CAS  Google Scholar 

  66. Jones LC, Hungerford DS. Cement disease. Clin Orthop 1987;225:192–206.

    PubMed  Google Scholar 

  67. Willert HG. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res 1977;11(2):157–164.

    Article  PubMed  CAS  Google Scholar 

  68. Charnley J. Fracture of femoral prostheses in total hip replacement: a clinical study. Clin Orthop 1975;111:105–120.

    Article  PubMed  Google Scholar 

  69. Ingham E, Fisher J. Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng [H] 2000;214(1):21–37.

    CAS  Google Scholar 

  70. Amstutz HC, Campbell P, Kossovsky N, Clarke IC. Mechanism and clinical significance of wear debris-induced osteolysis. Clin Orthop 1992;276:7–18.

    PubMed  Google Scholar 

  71. Howie DW, Haynes DR, Rogers SD, McGee MA, Pearcy MJ. The response to particulate debris. Orthop Clin North Am 1993;244:571–581.

    Google Scholar 

  72. Goodman SB, Fornasier VL, Lee J, Kei J. The histological effects of the implantation of different sizes of polyethylene particles in the rabbit tibia. J Biomed Mater Res 1990;24(4): 517–524.

    Article  PubMed  CAS  Google Scholar 

  73. Murray DW, Rushton N. Macrophages stimulate bone resorption when they phagocytose particles. J Bone Joint Surg Br 1990;72(6):988–992.

    PubMed  CAS  Google Scholar 

  74. Santavirta S, Hoikka V, Eskola A, et al. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg Br 1990;72(6):980–984.

    PubMed  CAS  Google Scholar 

  75. Kurtz SM, Rimnac C, Bartel D. Degradation rate of ultra-high molecular weight polyethylene. J Orthop Res 1997;15(1):57–61.

    Article  PubMed  CAS  Google Scholar 

  76. Eyerer P, Ke YC. Property of UHMW polyethylene hip cup endoprostheses during implantation. J Biomed Mater Res 1984;18(9):1137–1151.

    Article  PubMed  CAS  Google Scholar 

  77. Fisher J, Chan KL, Hailey JL, et al. Preliminary study of the effect of ageing following irradiation on the wear of ultrahigh-molecular-weight polyethylene. J Arthroplasty 1995;10(5):689–692.

    Article  PubMed  CAS  Google Scholar 

  78. Besong AA, Tipper JL, Ingham E, et al. Quantitative comparison of wear debris from UHMWPE that has and has not been sterilised by gamma irradiation. J Bone Joint Surg Br 1998;80(2):340–344.

    Article  PubMed  CAS  Google Scholar 

  79. Heisel C, Silva M, Schmalzried TP. Bearing surface options for total hip replacement in young patients. J Bone Joint Surg Am 2003;85(7):1366–1379.

    Google Scholar 

  80. Berry D. Editorial. Bearing surface options in total hip replacement. Semin Arthroplasty 2003;14:55–60.

    Google Scholar 

  81. Tipper JL, Firkins PJ, Besong AA et al. Characterisation of wear debris from UHMWPE on zirconia ceramic, metal-on-metal and alumina ceramic-on-ceramic hip prostheses generated in a physiological anatomical hip joint simulator. Wear 2001;250:120–128.

    Article  Google Scholar 

  82. Fisher J. Biomedical applications. In: Bhushan B, ed. Modern tribology handbook. Volume 2: materials, coatings and industrial applications. Boca Raton: CRC Press; 2001:1593–1609.

    Google Scholar 

  83. Fisher J, McEwen HMJ, Barnett PI et al. Mini-Symposium: Total knee replacement – practical considerations. (i) Wear of polyethylene in artificial knee joints. Curr Orthop 2001;15:399–405.

    Article  Google Scholar 

  84. Barnett PI, Fisher J, Auger DD, et al. Comparison of wear in a total knee replacement under different kinematic conditions. J Mater Sci Mater Med 2001;12(10–12):1039–1042.

    Article  PubMed  CAS  Google Scholar 

  85. McEwen HMJ, Fisher J, Goldsmith AAJ, et al. Wear of fixed bearing and rotating platform mobile bearing knees subjected to high levels of internal and external tibial rotation. J Mater Sci Mater Med 2001;12(10–12):1049–1052.

    Article  PubMed  CAS  Google Scholar 

  86. Emerton ME, Burton D. Mini-Symposium: Total knee replacement – practical considerations. (ii) The role of unicompartmental knee replacement. Curr Orthop 2001;15: 406–412.

    Article  Google Scholar 

  87. Boardman PL, Hart FD. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J 1967;4:264–268.

    PubMed  CAS  Google Scholar 

  88. Fraser TN. Gold treatment in rheumatoid arthritis. Br Med J 1945;50:471–475.

    Google Scholar 

  89. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone-compound E) and of the pituitary adreno-corticotrophic hormone on rheumatoid arthritis – preliminary report. Proc Staff Meetings Mayo Clinic 1949;24:181–197.

    CAS  Google Scholar 

  90. Sinclair RJG, Duffy JJR. Salazopyrin in the treatment of rheumatoid arthritis. Ann Rheum Dis 1948;8:226–231.

    Article  Google Scholar 

  91. Wickens S, Paulus HE. Antimalarial drugs. In: Paulus HE, Furst DE, Dromgoole SH, eds. Drugs for rheumatic disease. New York: Churchill Livingstone; 1987:113.

    Google Scholar 

  92. Multi-Centre Trial Group. Controlled trial of D-penicillamine in rheumatoid arthritis. Lancet 1973;1:275–285.

    Article  Google Scholar 

  93. Dixon AStJ, Davies J, Dormandy TL, et al. Synthetic D-penicillamine in rheumatoid arthritis – double-blind controlled study of a high and low-dose regimen. Ann Rheum Dis 1975;34:416–421.

    PubMed  CAS  Google Scholar 

  94. Davies J, Dormandy TL, et al. Synthetic D-penicillamine in rheumatoid arthritis – double-blind controlled study of a high and low-dose regimen. Ann Rheum Dis 1975;34:416–421.

    PubMed  Google Scholar 

  95. Girgis L, Conaghan PG, Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine. Curr Opin Rheumatol. 1994;6(3):252–261.

    Article  PubMed  CAS  Google Scholar 

  96. American College of Rheumatology Subcommittee on Rheumatoid Arthritis guidelines. Guidelines for the management of Rheumatoid Arthritis. Arthritis Rheum 2002;46(2): 328–346.

    Article  CAS  Google Scholar 

  97. Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906–914.

    Article  PubMed  CAS  Google Scholar 

  98. Albers JM, Paimela L, Kurki P, et al. Treatment strategy, disease activity and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:453–458.

    Article  PubMed  CAS  Google Scholar 

  99. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627–633.

    Article  PubMed  CAS  Google Scholar 

  100. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–740.

    Article  PubMed  CAS  Google Scholar 

  101. Goldsmith CH, Boers M, Bombardier C, Tugwell P, for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring, and evaluation of the rheumatoid arthritis patient and trial profiles. J Rheumatol 1993;20:561–565.

    PubMed  CAS  Google Scholar 

  102. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39 (Suppl 1):24–29.

    PubMed  Google Scholar 

  103. Kroot EJ, deBong JA, van Leeuwen MA, et al. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43(8):1831–1835.

    Article  PubMed  CAS  Google Scholar 

  104. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis: the Arthritis Impact Measurement Scales. Arthritis Rheum 1980;23:146–152.

    Article  PubMed  CAS  Google Scholar 

  105. Paulus HE, Egger MJ, Ward JR, et al., and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477–484.

    Article  PubMed  CAS  Google Scholar 

  106. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308–1315.

    Article  PubMed  CAS  Google Scholar 

  107. Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical, and laboratory abnormalities. Arthritis Rheum 1971;14:706–720.

    Article  PubMed  CAS  Google Scholar 

  108. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326–1335.

    Article  PubMed  CAS  Google Scholar 

  109. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26–34.

    Article  PubMed  Google Scholar 

  110. Bell MJ, Lineker SC, Wilkens AL, et al. A randomized controlled trial to evaluate the efficacy of community based physical therapy in treatment of people with rheumatoid arthritis. J Rheumatol 1998;25:231–237.

    PubMed  CAS  Google Scholar 

  111. Komatireddy GR, Leitch RW, Cella K, et al. Efficacy of low resistance muscle training in patients with rheumatoid arthritis functional class II and III. J Rheumatol 1997;24: 1531–1539.

    PubMed  CAS  Google Scholar 

  112. Neuberger GB, Press AN, Lindsey HB, et al. Effects of exercise on fatigue, aerobic fitness, and disease activity measures with rheumatoid arthritis. Res Nurs Health 1997;20: 195–204.

    Article  PubMed  CAS  Google Scholar 

  113. Van den Ende CH, Vliet Vlieland TP, Munneke M, et al. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. Br J Rheumatol 1998;37:677–687.

    Article  PubMed  Google Scholar 

  114. Bombardier C, Laine L, Reicin A, et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  115. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA 2000;284:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  116. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–1899.

    Article  PubMed  CAS  Google Scholar 

  117. Yeomans ND, Tulassay Z, Juhasz L, et al, for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719–726.

    Article  PubMed  CAS  Google Scholar 

  118. Hawkey CJ, Karrasch JA, Szczepanski L, et al., for the Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727–734.

    Article  PubMed  CAS  Google Scholar 

  119. Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142–46.

    Article  PubMed  CAS  Google Scholar 

  120. Gubner R, August S, Ginsburg V. Therapeutic suppression of tissue reactivity:II. Effect of aminopterin in rheumatoid arthritis and psoriatic arthritis. Am J Med Sci 1951; 221:176.

    Article  PubMed  CAS  Google Scholar 

  121. Fehlauer SC, Carson CW, Cannon GW. Two year follow up of treatment of rheumatoid arthritis with methotrexate: clinical experience in 124 patients. J Rheumatol 1989;16: 307–312.

    PubMed  CAS  Google Scholar 

  122. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheum 1994;37:1492–1498.

    Article  PubMed  CAS  Google Scholar 

  123. Suarez-Almazor ME, Belseck E, Shea B, et al. Methotrexate for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 4, 2001 Oxford: Update Software.

    Google Scholar 

  124. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits for increasing folic acid intakes. JAMA 1995;274:1040–1057.

    Article  Google Scholar 

  125. Landewe RBM, van der Borne BEEM, Breedveld FC, et al. Methotrexate effects in patients with Rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000;355: 1616–1617.

    Article  PubMed  CAS  Google Scholar 

  126. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta­analysis. BMJ 2002;325:1202–1208.

    Article  PubMed  Google Scholar 

  127. Arnesen E, Refsum H, Bonna KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704–709.

    Article  PubMed  CAS  Google Scholar 

  128. Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinaemia during longterm low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441–446.

    PubMed  CAS  Google Scholar 

  129. Van Ede AE, Laan RFJM, Blom HJ, et al. Homocysteine and folate status in methotrexate treated patients with Rheumatoid arthritis. Rheumatology 2002;41:658–665.

    Article  PubMed  Google Scholar 

  130. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992;19:704–708.

    PubMed  CAS  Google Scholar 

  131. Morgan SL, Baggott JE, Vaughan WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo controlled trial. Ann Intern Med 1994;121:833–841.

    PubMed  CAS  Google Scholar 

  132. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795–803.

    Article  PubMed  CAS  Google Scholar 

  133. Kremer JM, Alarco’n GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316–328.

    Article  PubMed  CAS  Google Scholar 

  134. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1: 1036–1038.

    PubMed  Google Scholar 

  135. Van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996;124:699–707.

    PubMed  Google Scholar 

  136. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3-year follow-up on the Hydroxychloroquine in Early Rheumatoid Arthritis (HERA) study. J Rheumatol 2000;27:623–629.

    PubMed  CAS  Google Scholar 

  137. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993;119:1067–1071.

    PubMed  CAS  Google Scholar 

  138. Blackburn WDJr, Prupas HM, Silverfield JC, et al. Tenidap in rheumatoid arthritis: a 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 1995;38:1447–1456.

    Article  PubMed  CAS  Google Scholar 

  139. Runge LA. Risk/benefit analysis of hydroxychloroquine sulphate treatment in rheumatoid arthritis. Am J Med 1983;75(1A):52.

    Article  PubMed  CAS  Google Scholar 

  140. O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287–1291.

    Article  PubMed  CAS  Google Scholar 

  141. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353: 1568–1573.

    Article  PubMed  Google Scholar 

  142. O’Dell J, Leff R, Paulsen G, et al. Methotrexate (M)-hydroxychloroquine (H)-sulfasalazine (S) versus M-H or M-S for rheumatoid arthritis (RA): results of a double-blind study [abstract]. Arthritis Rheum 1999;42(Suppl 9):S117.

    Google Scholar 

  143. Landewe’ RB, Goei The‘ HS, van Rijthoven AWAM, et al. A randomized, double- blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637–643.

    Article  CAS  Google Scholar 

  144. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–266.

    Article  PubMed  CAS  Google Scholar 

  145. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702–713.

    Article  PubMed  CAS  Google Scholar 

  146. Ebringer R, Ahern M, Thomas D, et al, for the Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992;19:1672–1677.

    Google Scholar 

  147. Skosey JL. Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis. J Rheumatol Suppl 1998;16:5–8.

    Google Scholar 

  148. Sharp JT, Strand V, Leung H, et al., on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495–505.

    Article  PubMed  CAS  Google Scholar 

  149. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542–2550.

    Article  PubMed  CAS  Google Scholar 

  150. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595–1603.

    Article  PubMed  CAS  Google Scholar 

  151. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. J Rheumatol 2000;39:655–665.

    Article  CAS  Google Scholar 

  152. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomised controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870–1878.

    Article  PubMed  CAS  Google Scholar 

  153. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000;43:506–514.

    Article  PubMed  CAS  Google Scholar 

  154. Forestier J. Rheumatoid arthritis and its treatment with gold salts. J Lab Clin Med 1935;20:827.

    Google Scholar 

  155. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368–1375.

    Article  PubMed  CAS  Google Scholar 

  156. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two meta-analyses. Arthritis Rheum 190;33: 1449–1461.

    Google Scholar 

  157. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983;26:1303–1315.

    Article  PubMed  CAS  Google Scholar 

  158. Van Rijthoven AW, Dijkmans BA, Goei The‘ HS, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum 1986;45: 726–731.

    Google Scholar 

  159. Wells G, Haguenauer D, Shea B, et al. Cyclosporine for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 4, 2001 Oxford: Update Software.

    Google Scholar 

  160. Van den Borne BEEM, Landewe’ RBM, Goei The‘ HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493–1498.

    PubMed  Google Scholar 

  161. Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992;93:396–402.

    Article  PubMed  CAS  Google Scholar 

  162. Boers M, Dijkmans BA, van Rijthoven AW, et al. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 1990;17:38–42.

    PubMed  CAS  Google Scholar 

  163. Levy J, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis [abstract]. Arthritis Rheum 1972;15:116–117.

    Google Scholar 

  164. Urowitz MB, Gordon DA, Smythe HA, et al. Azathioprine in rheumatoid arthritis: a double-blind, crossover study. Arthritis Rheum 1973;16:411–418.

    Article  PubMed  CAS  Google Scholar 

  165. Woodland J, Chaput de Saintonge DM, et al. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses verses placebo. Ann Rheum Dis 1981;40:355–359.

    PubMed  CAS  Google Scholar 

  166. Clunie GPR, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving Azathioprine. Rheumatology 2004;43:13–18.

    Article  PubMed  CAS  Google Scholar 

  167. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629–636.

    Article  PubMed  CAS  Google Scholar 

  168. Tilley BC, Alarco’n GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81–88.

    PubMed  CAS  Google Scholar 

  169. O’Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized double-blind, placebo controlled trial. Arthritis Rheum 1997;40:842–848.

    Article  PubMed  CAS  Google Scholar 

  170. O’Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year follow up of a double-blind, placebo controlled trial. Arthritis Rheum 1999;42:1691–1695.

    Article  PubMed  CAS  Google Scholar 

  171. Alarco’n GS, Bartolucci AA. Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline. J Rheumatol 2000;27: 530–534.

    CAS  Google Scholar 

  172. Hickling P, Jacoby RK, Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930–936.

    Article  PubMed  CAS  Google Scholar 

  173. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791–801.

    Article  Google Scholar 

  174. Royal College of Physicians (UK). Osteoporosis: clinical guidelines for prevention and management. London: RCP; 1999.

    Google Scholar 

  175. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22: 1055–1059.

    PubMed  CAS  Google Scholar 

  176. Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999;42:1740–1751.

    Article  PubMed  CAS  Google Scholar 

  177. Garber EK, Targoff C, Paulus HE. Corticosteroids in the rheumatic diseases: Chronic low doses, chronic high doses, “pulses”, intra-articular. In: Paulus HE, Furst DE, Dromgoole SH, eds. Drugs for rheumatic disease. New York: Churchill Livingstone; 1987: 443.

    Google Scholar 

  178. Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131:768–774.

    PubMed  CAS  Google Scholar 

  179. Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259–269.

    Article  PubMed  CAS  Google Scholar 

  180. Haagsma CJ, van Reil PL, de Jong AJ, et al. Combination of sulfasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082–1088.

    Article  PubMed  CAS  Google Scholar 

  181. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulfasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58: 220–225.

    Article  PubMed  CAS  Google Scholar 

  182. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322–1328.

    Article  PubMed  CAS  Google Scholar 

  183. Kremer JM, Caldwell JR, Cannon GW, et al. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: a double-blind placebo controlled study [abstract]. Arthritis Rheum 2000;43(Suppl 9):S224.

    Google Scholar 

  184. Furst DE, Luggen ME, Thompson AK, et al. Adding leflunomide to patients with active rheumatoid arthritis while receiving methotrexate improves physical function and healthrelated quality of life [abstract]. Arthritis Rheum 2000;43(Suppl 9):S344.

    Google Scholar 

  185. Salaffi F, Carotti M, Cervini C. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996;25:16–23.

    Article  PubMed  CAS  Google Scholar 

  186. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137–141.

    Article  PubMed  CAS  Google Scholar 

  187. Cook SD, Beckenbaugh RD, Redondo J, et al. Long-term follow-up of pyrolytic carbon metacarpophalangeal implants. J Bone Joint Surg Am 1999;81:635–648.

    PubMed  CAS  Google Scholar 

  188. Creighton MG, Callaghan JJ, Olejniczak JP, et al. Total hip arthroplasty with cement in patients who have rheumatoid arthritis: a minimum ten-year follow-up study. J Bone Joint Surg Am 1998;80:1439–1446.

    PubMed  CAS  Google Scholar 

  189. Mont MA, Yoon TR, Krackow KA, et al. Eliminating patellofemoral complications in total knee arthroplasty: clinical and radiographic results of 121 consecutive cases using the Duracon system. J Arthroplasty 1999;14:446–455.

    Article  PubMed  CAS  Google Scholar 

  190. Ranawat CS. Surgical management of the rheumatoid hip. Rheum Dis Clin North Am 1998;24:129–141.

    Article  PubMed  CAS  Google Scholar 

  191. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072–1082.

    Article  PubMed  CAS  Google Scholar 

  192. Escalante A, Beardmore TD. Predicting length of stay after hip or knee replacement for rheumatoid arthritis. J Rheumatol 1997;24:146–152.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Previously Clinical Lecturer in Rheumatology and Medical Education, Academic Unit of Medical Education, University of Sheffield, Sheffield, UK

    Shirish Dubey

Authors
  1. Shirish Dubey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adewale O. Adebajo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK

    David M. Reid MBChB, MD, FRCP

  2. Bio-Imaging Technologies Inc, Newtown, PA, USA

    Colin G. Miller BSc, PhD, FICR

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Dubey, S., Adebajo, A.O. (2008). Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. In: Reid, D.M., Miller, C.G. (eds) Clinical Trials in Rheumatoid Arthritis and Osteoarthritis. Clinical Trials. Springer, London. https://doi.org/10.1007/978-1-84628-742-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-742-8_2

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-874-9

  • Online ISBN: 978-1-84628-742-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation